Progestin-primed ovarian stimulation for fertility preservation in women with cancer: A comparative study
PLOS ONE · 2023
DOI: 10.1371/journal.pone.0280238 ↗Kurz gefasst
Fachartikel in der Zeitschrift PLOS ONE, 2023. Verfasst von Francesca Filippi und 8 weiteren Autor:innen. Beteiligte Einrichtung: Infertility Unit, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy. Hauptthemen laut MEDLINE: Fertility Preservation, Infertility, Female, Neoplasms. Die Arbeit wurde bisher 20-mal zitiert (Crossref) und nennt 33 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Italian Ministry of Health - Current research IRCCS.
Abstract (Originalsprache)
Background
In women scheduled for cancer treatment, oocytes cryopreservation is a well-established procedure. Random start protocols have been a substantial improvement in this setting, allowing to prevent delay in the initiation of cancer treatments. However, there is still the need to optimize the regimen of ovarian stimulation, to make treatments more patient-friendly and to reduce costs.
Methods
This retrospective study compares two periods (2019 and 2020), corresponding to two different ovarian stimulation regimens. In 2019, women were treated with corifollitropin, recombinant FSH and GnRH antagonists. Ovulation was triggered with GnRH agonists. In 2020, the policy changed, and women were treated with a progestin-primed ovarian stimulation (PPOS) protocol with human menopausal gonadotropin (hMG) and dual trigger (GnRH agonist and low dose hCG) Continuous data are reported as median [Interquartile Range]. To overcome expected changes in baseline characteristics of the women, the primary outcome was the ratio between the number of mature oocytes retrieved and serum anti-mullerian hormone (AMH) in ng/ml.
Results
Overall, 124 women were selected, 46 in 2019 and 78 in 2020. The ratio between the number of mature oocytes retrieved and serum AMH in the first and second period was 4.0 [2.3–7.1] and 4.0 [2.7–6.8], respectively (p = 0.80). The number of scans was 3 [3–4] and 3 [2–3], respectively (p
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Infertility Unit, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy.
- Department of Clinical Sciences and Community Health, Università Degli Studi di Milano, Milan, Italy.
- Environmental and Industrial Toxicology Unit, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy.
- Centre for Reproductive Medicine, Universitair Ziekenhuis Brussel, Vrije Universiteit Brussel, Brussels, Belgium.
ORCID-Profile: Francesca Filippi
Förderung
- Italian Ministry of Health - Current research IRCCS
Zitieren
APA
Filippi, F., Reschini, M., Polledri, E., Cecchele, A., Guarneri, C., Vigano, P., Fustinoni, S., Platteau, P., & Somigliana, E. (2023). Progestin-primed ovarian stimulation for fertility preservation in women with cancer: A comparative study. PLOS ONE. https://doi.org/10.1371/journal.pone.0280238
Vancouver
Filippi F, Reschini M, Polledri E, Cecchele A, Guarneri C, Vigano P, et al. Progestin-primed ovarian stimulation for fertility preservation in women with cancer: A comparative study. PLOS ONE. 2023. doi:10.1371/journal.pone.0280238
BibTeX
@article{Filippi2023,
author = {Filippi, Francesca and Reschini, Marco and Polledri, Elisa and Cecchele, Anna and Guarneri, Cristina and Vigano, Paola and Fustinoni, Silvia and Platteau, Peter and Somigliana, Edgardo},
title = {Progestin-primed ovarian stimulation for fertility preservation in women with cancer: A comparative study},
journal = {PLOS ONE},
year = {2023},
doi = {10.1371/journal.pone.0280238}
}
EUVIMED